BioPharma Resources

Drug Trial Radar · NCT07319871

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 14, 2026

Primary completion

Jan 7, 2027

Study completion Mar 15, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.

Conditions

  • Prostatic Neoplasms

Interventions

  • PasritamigDrug

    Pasritamig will be administered intravenously.

  • JNJ-86974680Drug

    JNJ-86974680 will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) by SeverityTime frame: Up to 1 year 2 months
  2. Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)Time frame: Up To Day 22

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • The Christie NHS Foundation Trust Christie Hospital

    Manchester, United Kingdom · Recruiting

  • Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.